72 results about "Infectious bursitis" patented technology

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and an infectious bursal disease virus supervirulent strain VP2 gene and application thereof, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus super virulent strain VP2 gene is inserted into a spacer region between Marek's disease virus genome UL45 and UL46 genes; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus super virulent strain VP2 gene expression framework are inserted between Marek's disease virus genome UL45 and UL46 genes, and a recombinant virus C20101 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus super virulent strain VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant Marek's disease virus strain provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and Marek's disease at the same time, and has a good market application prospect.

The invention relates to the technical field of biological medicines, and particularly discloses a preparation method and application of intestinal tract targeted DNA (deoxyribonucleic acid) nano origame.The preparation method is technically characterized by comprising the following steps: S1, synthesizing planar DNA nano origametes (DONs); s2, assembling the DONs and the siRNA (small interfering ribonucleic acid); and S3, synthesizing the tubular DNA nano origami loaded with siRNA: uniformly mixing the purified DONs-siRNA origami with 10 times of excessive APE1 chain and cross-linked chain, annealing from 45 DEG C to 25 DEG C, and synthesizing the tubular DNA nano origami. According to the method disclosed by the invention, a nano delivery carrier which has intestinal targeting, is accurately loaded and can release siRNA as required is developed by utilizing a DNA (Deoxyribonucleic Acid) nano technology, so that efficient treatment of IBD (Infectious Bursal Disease) by siRNA is realized.

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.

The invention relates to an infectious bursal disease virus VP3 phosphorylated deletion virus as well as a construction method and application thereof. Specifically, the invention provides the infectious bursal disease virus VP3 phosphorylation deletion virus, the infectious bursal disease virus VP3 phosphorylation deletion virus comprises a mutant plasmid and a rescue vector loaded with the mutant plasmid, and mutation points of the mutant plasmid are as follows: 130th serine of VP3 protein is mutated into alanine and 163rd serine is mutated into alanine. The infectious bursal disease virus VP3 phosphorylation deletion virus provided by the invention can be used as a powerful tool for researching an infectious bursal disease virus VP3 phosphorylation mechanism.

The application provides application of a formulation of Usnea, Usnic acid or Usnic acid salt in preparation of a product for preventing and treating infectious bursal disease of poultry or complications caused by infection. The application can achieve an outstanding effect of resisting chicken infectious bursal disease by adding the formulation of Usnea or Usnic acid and its salt in feed or water. Meanwhile, the formulation of Usnea or Usnic acid and its salt is low in cost and simple in application as a means of resisting chicken infectious bursal disease, and is beneficial to large-scale promotion.

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and a novel variant VP2 gene of an infectious bursal disease virus and application of the recombinant Marek's disease virus, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus novel variant VP2 gene is inserted between 105561-105563 nucleotides of a serum type 1 chicken Marek's disease virus CVI988 strain genome; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus novel variant VP2 gene expression framework are inserted into a chicken Marek's disease virus genome, and a recombinant virus C20103 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus novel variant VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant chicken Marek's disease virus provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and chicken Marek's disease at the same time, and has a good market application prospect.

The invention relates to a traditional Chinese medicine preparation for treating infectious bursal disease as well as a preparation method and application of the traditional Chinese medicine preparation. The medicament is prepared from the following raw material components: 45 to 50 parts of radix astragali, 30 to 45 parts of radix rehmanniae, 25 to 30 parts of radix isatidis, 25 to 30 parts of folium isatidis, 10 to 45 parts of gypsum, 10 to 20 parts of honeysuckle flower, 10 to 30 parts of fructus forsythiae, 10 to 20 parts of herba taraxaci, 15 to 20 parts of rhizoma atractylodis macrocephalae, 15 to 30 parts of radix paeoniae rubra, 15 parts of bulbus lilii, 15 parts of rhizoma anemarrhenae and 10 to 30 parts of liquorice root. The medicament is prepared by extraction and concentration processes, and can effectively treat the chicken infectious bursal disease caused by the traditional infectious bursal disease virus (IBDV) and the novel variable infectious bursal disease virus (nvvIBDV). The medicine can significantly improve the cure rate of traditional and variant strains, and especially has significant advantages in the treatment of variant strains.

This invention relates to a traditional Chinese medicine preparation for treating infectious bursal disease (IBD), its preparation method, and its application. The preparation comprises the following components: Astragalus membranaceus 45-50 parts, Rehmannia glutinosa 30-45 parts, Isatis indigotica 25-30 parts, Isatis tinctoria 25-30 parts, Gypsum fibrosum 10-45 parts, Lonicera japonica 10-20 parts, Forsythia suspensa 10-30 parts, Taraxacum mongolicum 10-20 parts, Atractylodes macrocephala 15-20 parts, Paeonia lactiflora 15-30 parts, Lilium brownii 15 parts, Anemarrhena asphodeloides 15 parts, and Glycyrrhiza uralensis 10-30 parts. The preparation is achieved through extraction and concentration processes and is effective in treating IBD in chickens caused by both traditional infectious bursal disease virus (IBDV) and novel variant infectious bursal disease virus (nvvIBDV). This medicine significantly improves the cure rate against both traditional and variant strains, showing a particularly significant advantage in treating variant strains.

The invention discloses a method for removing endotoxin in chicken infectious bursal disease virus VP2 protein. The method comprises the following steps: firstly, crushing a VP2 protein expression strain; adding calcium chloride into the treated VP2 protein, and standing; returning the temperature, adding sodium carbonate into the VP2 protein subjected to temperature returning, and standing; and returning the temperature of the VP2 protein added with the sodium carbonate, taking supernate, adding calcium chloride into the supernate, and standing. By setting the adding concentration of calcium chloride, the adding concentration of sodium carbonate and the treatment sequence and times of calcium chloride and sodium carbonate, the endotoxin in the VP2 protein is efficiently and rapidly removed by using calcium chloride and sodium carbonate. By adopting the method disclosed by the invention, the endotoxin removal rate reaches 99.91%, the agar diffusion titer is improved compared with that before treatment, and the animal vaccine preparation standard is met. The method disclosed by the invention is short in treatment period, large in treatment capacity, low in removal cost and suitable for industrial mass production.

The invention relates to the technical field of biological nucleic acid detection, in particular to a primer combination, a detection method and a kit for detecting virulent strains and variants of infectious bursal disease viruses. The primer probe combination comprises three pairs of specific primer probes designed according to VP2 gene segments of a virulent strain, a variant 1 and a variant 2 of the infectious bursal disease virus, and the sequences of the three pairs of primers are as shown in SEQ ID NO: 1-9. The primer probe combination provided by the invention can achieve the purpose of distinguishing and detecting different strains of IBDV through fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction). The primer probe combination provided by the invention has the advantages of high sensitivity, strong specificity and the like, and provides a new effective detection means for rapid differential diagnosis of IBDV, epidemiological investigation and prevention and control of IBD clinically.

The invention belongs to the technical field of traditional Chinese medicine, and provides a traditional Chinese medicine composition for treating inflammatory bowel disease and a preparation method thereof, the traditional Chinese medicine composition comprises the following raw materials by weight: 0.5-5 parts of ginseng, 4-20 parts of Radix Astragali, 3-20 parts of Rhizoma Polygonati, 0.5-6 parts of licorice, 0.5-6 parts of cassia twig, 0.5-5 parts of processed monkshood, and 1-9 parts of ginger. The pharmaceutical composition disclosed by the invention consists of ginseng, astragalus membranaceus, rhizoma polygonati, liquorice, cassia twig, radix aconiti carmichaeli praeparata and ginger, is used for treating and conditioning IBD (Infectious Bursal Disease) with unknown etiology, and has a remarkable effect.

The application belongs to the technical field of biological medicine, and discloses a method for preparing an avian infectious bursal disease VP2 nanoparticle oral vaccine by using Kluyveromyces marxianus and application thereof. The applicant assembles and prepares a double replicon expression vector suitable for Kluyveromyces marxianus through screening, and the vector achieves the effect of high conversion rate and high expression efficiency in Kluyveromyces marxianus. The double replicon expression vector pGKD32 is shown in SEQ ID NO. 2. The applicant successfully expresses the avian infectious bursal disease VP2 in the form of nanoparticles by using the Kluyveromyces marxianus expression system provided in the application, and provides a new idea for the research and development of the avian infectious bursal disease virus oral immunization strategy.

This application relates to an infectious bursal disease virus (IBDV) VP3 phosphorylation-deficient virus, its construction method, and its applications. Specifically, this application provides an IBDV VP3 phosphorylation-deficient virus, including a mutant plasmid and a rescue vector carrying the mutant plasmid. The mutant plasmid has the following mutations: serine 130 to alanine and serine 163 to alanine in the VP3 protein. The IBDV VP3 phosphorylation-deficient virus provided in this application can serve as a powerful tool for studying the phosphorylation mechanism of IBDV VP3.

The invention discloses colloidal gold immunochromatography test paper for rapidly detecting pigeon I-type paramyxovirus and a preparation method of the colloidal gold immunochromatography test paper. Viral diseases of pigeons, especially pigeon plague virus and pigeon adenovirus, are rapidly detected on the basis of a newly developed test strip, and the operation is simple and convenient; according to the design of antigens and antibodies of the pigeon plague virus and the pigeon adenovirus, rapid detection of the pigeon plague virus and the pigeon adenovirus can be conveniently carried out, and the obtained test strip is high in specificity and high in sensitivity. The pigeon I-type paramyxovirus detection kit has the advantages that the pigeon I-type paramyxovirus detection kit does not have cross reaction with chicken infectious bronchitis, chicken egg drop syndrome, chicken Marek's disease, avian influenza, fowl adenovirus, infectious bursal disease, escherichia coli, salmonella and other samples, but can have cross reaction with Newcastle disease, so that the pigeon I-type paramyxovirus detection kit can be used for diagnosing pigeon I-type paramyxovirus and Newcastle disease.

A composition, an in ovo vaccine, and a composition for use as a vaccine against coccidiosis. The compositions and vaccine include Eimeria oocysts from a precocious attenuated strain of E. acervulina, and from at least one precocious attenuated strain selected from E. maxima, E. praecox and E. tenella. The composition and vaccine can be administered in ovo to embryonated eggs of a domesticated bird. A combination vaccine for use in the prevention and / or treatment of an Eimeria infection and Infectious Bursal Disease (Gumboro disease) and a kit for use as a vaccine including the composition.

The invention discloses an IBDV (Infectious Bursal Disease Virus) mutant based on VP1 protein T425 and R426 synergistic modification and application of the IBDV mutant. The invention identifies that threonine at the 425th site on the VP1 protein is a new phosphorylation site for the first time, and reveals that threonine at the 425th site and adjacent arginine methylation modification at the 426th site have a synergistic positive feedback regulation relationship. Based on the mechanism, a T425 and R426 double-site modification deleted virus mutant is successfully constructed, and the mutant shows a phenotype with severely weakened replication ability. In addition, the invention also provides an antibody capable of specifically recognizing pT425, an application of a GSK-3 kinase inhibitor in inhibition of virus replication, and a related screening and detection method. The invention provides a new target and strategy for developing novel IBDV attenuated vaccines, antiviral drugs and diagnostic reagents.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mesenchymal stem cells combined with mesalazine in preparation of an anti-IBD (infectious bursal disease) medicine. The mesenchymal stem cells are mesenchymal stem cells from human umbilical cord; the human umbilical cord mesenchymal stem cells highly express CD73, CD90 and CD65, and low express CD34, CD45 and HLA-DR (Human Leukocyte Antigen-DR). The research finds that the hUC-MSCs has a remarkable treatment effect on a chronic IBD mouse model when being singly used or combined with 5-ASA for treatment, the hUC-MSCs and drug combination can restore the intestinal microecological balance by adjusting the composition of intestinal flora so as to improve the symptoms of IBD, and the hUC-MSCs and the drug combination have a synergistic effect when being combined with 5-ASA for treatment. The invention provides a new thought and experimental basis for clinical treatment of IBD.

The invention belongs to the technical field of preparation of nano composite materials, and particularly relates to a tungsten-doped Prussian blue nano composite material, a preparation method and application. The tungsten-doped Prussian blue nano composite material prepared by a one-pot hydrothermal method by taking polyvinylpyrrolidone as a reducing agent and a stabilizer and tungsten hexachloride, citric acid and potassium ferricyanide as reactants has excellent ROS (reactive oxygen species) removal capability and can protect intestinal epithelial cells and treat IBD (infectious bursal disease), and hydrogel is further taken as a carrier to prepare a colon-targeted delivery material. The W-PB is protected to be accurately delivered to the colon, the hydrogel is disintegrated to release the W-PB under the subsequent alkaline environment, and then W ions are further released, so that responsive release of the colon is achieved, and systemic toxicity of the W ions is avoided.

The invention discloses a chicken infectious bursal disease virus VP2 protein, a VP2 protein virus-like particle vaccine and a preparation method thereof. The method comprises the following steps: firstly, optimally designing an IBDV VP2 protein; secondly, a pCold II-SUMO prokaryotic expression vector is obtained by adding SUMO protein on the basis of an escherichia coli cold shock expression vector pCold II, the prokaryotic soluble expression efficiency of the VP2 protein is improved, and the concentration of the purified VP2 protein with the SUMO label can reach 1.00 mg / mL; after the SUMO label is removed, the VP2 protein can be 100% assembled into VLPs in a specific solution, and after emulsification-demulsification, the VP2 protein still keeps a complete VLPs structure instead of a VP2 monomer, the stability is good, and experimental results show that the VLPs vaccine can 100% protect SPF chicken from IBDV virulent virus attack. Besides, the preparation method of the VP2 protein is simple, molecular sieve chromatography purification with high cost is avoided, complex processes such as ultracentrifugation are not needed, the recovery rate of two-step affinity purification is close to 60%, the purity of the purified VP2 protein is about 80%, and industrial-scale preparation of IBDV structural protein and IBDV VLPs vaccines becomes possible.

The present invention provides a recombinant Marek's disease virus that co-expresses the Newcastle disease virus F gene and the infectious bursal disease virus new variant VP2 gene and its application, belonging to the field of genetically engineered vaccines. The present invention utilizes recombinant cloning technology to insert an expression framework comprising the Newcastle disease virus gene type VII strain F gene and the infectious bursal disease virus new variant VP2 gene into the serotype 1 chicken Marek's disease virus CVI988 strain genome between nucleotides 105561-105563, constructing a recombinant cosmid in which the Newcastle disease virus F gene and the infectious bursal disease virus new variant VP2 gene expression framework are inserted into the chicken Marek's disease virus genome, and the recombinant virus C20103 strain that co-expresses the Newcastle disease virus F gene and the infectious bursal disease virus new variant VP2 gene is rescued by the recombinant Marek's disease virus. The vaccine prepared by the recombinant chicken Marek's disease virus provided by the present invention can simultaneously prevent Newcastle disease, infectious bursal disease and chicken Marek's disease, and has good market application prospects.

The invention provides a radix astragali and blue antitoxic composition, a preparation method and a traditional Chinese medicine preparation. The astragalus membranaceus and indigowoad leaf antitoxic composition comprises an active component and an absorption enhancer, wherein the active component is prepared from the following components: astragalus membranaceus, indigowoad root, indigowoad leaf, rehmannia, hawthorn, codonopsis pilosula, bighead atractylodes rhizome and chrysanthemum. According to the present invention, the raw material types are subjected to addition and subtraction compatibility, such that the herbs supplement each other, the composition prepared from the 8 drug extracts provides the significant effect in the treatment of the chicken infectious bursal disease, and the absorption enhancer is added to discover that the sodium alginate grafted beta-cyclodextrin can promote the intestinal tract to absorb the active substances so as to provide the significant treatment effect on the chicken infectious bursal disease; the treatment effect is better. The medicine prepared from the composition can quickly stop diarrhea and bleeding, shorten the recovery time of animals and improve the treatment efficiency. In addition, compared with western medicines, the medicine has small side effects on animals, is easy to store, and has better safety and tolerance.

A vaccine includes a recombinant herpesvirus of turkeys (HVT) vector. The HVT vector has a heterologous polynucleotide coding for and expressing an Infectious Bursal Disease Virus (IBDV) viral protein 2 (VP2) antigen and a heterologous polynucleotide coding for and expressing an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen. The two heterologous polynucleotides are inserted into one locus in a non-essential region of the HVT genome selected from intergenic region 1 locus, intergenic region 2 locus, intergenic region 3 locus, UL43 locus, US10 locus, US2 locus, and SORF3 / US2 locus. The two heterologous polynucleotides are linked by internal ribosome entry site (IRES). The expression of the two heterologous polynucleotides is driven by a cytomegalovirus (CMV) immediate early (IE) promoter.

The invention discloses a recombinant herpesvirus turkey for co-expressing chicken infectious anemia virus VP1 and VP2 genes and an infectious bursal disease virus VP2 gene as well as a construction method and application of the recombinant herpesvirus turkey, and belongs to the technical field of medicine or veterinary medicine. According to the invention, by using a recombinant cloning technology, chicken infectious anemia virus VP1 and VP2 gene expression cassettes are inserted between 95322-95323 nucleotides of a turkey herpesvirus FC126 strain, and meanwhile, an infectious bursal disease virus VP2 gene expression cassette is inserted between 112071-112088 nucleotides of a genome of the turkey herpesvirus FC126 strain; and rescuing to obtain the recombinant turkey herpesvirus vaccine strain for co-expressing the chicken infectious anemia virus VP1 and VP2 genes and the infectious bursal disease virus VP2 gene. The invention provides a more convenient and effective technical means for simultaneously preventing chicken infectious anemia and chicken infectious bursal disease, and can achieve the effect of preventing multiple diseases by one injection.

The invention discloses a vaccine composition, an immunogen of the vaccine composition is a fusion protein containing a VP2 protein of a new isolate of chicken infectious bursal disease and an auxiliary protein, and the immunogen can be independently assembled into subvirus particles. The vaccine composition has good safety to chickens, the titer of an antibody generated by immunizing the chickens is high, and the challenge protection effect of the immunized chickens is good. The vaccine has an application prospect.

The present invention refers in general to the field of veterinary medicine and especially to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), avian infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease virus, avian influenza virus (AIV), infectious bronchitis virus (IBV).

The invention relates to a vaccine efficient combined immunization method for reducing stress of breeding hens, belongs to the technical field of animal epidemic prevention, and mainly solves the problems of multiple kinds of epidemic diseases needing to be prevented, multiple kinds of vaccination, multiple inoculation and injection times, high stress, inaccurate injection dosage, poor immunization effect and the like in breeding of the breeding hens. The invention provides a set of inactivated vaccine mixing device. According to the invention, an assembled inactivated vaccine mixing device is applied, and on the basis of a breeder's original immunization plan and injection vaccination vaccine types, by changing the vaccination mode, one-time injection and vaccination of various vaccines are realized; the total number of times of injection and inoculation in the whole feeding period is reduced, however, the number of times of single epidemic disease vaccine stimulation is large, inoculation stress is reduced, the inoculation dosage is more accurate, the response capacity of chickens to vaccines is improved, the antibody titer after immunization is high, the protection rate is high, meanwhile, the vaccine immunization workload is reduced, and the breeding chicken feeding benefits are improved. The method is mainly used for preventive inoculation of inactivated vaccines for avian influenza, Newcastle disease, infectious bursal disease, mycoplasmosis, infectious bronchitis, infectious rhinitis, egg drop syndrome and other epidemic diseases of breeding hens, and can also be popularized to immunization of other animal inactivated vaccines.

The invention discloses a recombinant turkey herpesvirus strain as well as a construction method and application thereof, and belongs to the technical field of medicine or veterinary medicine. The recombinant turkey herpesvirus is a recombinant turkey herpesvirus strain co-expressing a Newcastle disease virus F gene and infectious laryngotracheitis virus gB, gD and gI genes or a recombinant turkey herpesvirus strain co-expressing a Newcastle disease virus F gene, a chicken infectious bursal disease virus VP2 gene and infectious laryngotracheitis virus gB, gD and gI genes. The recombinant turkey herpesvirus strain obtained by the invention has good in-vitro replication ability and genetic stability. Safety and immunogenicity experiments prove that the two recombinant turkey herpesvirus strains are safe to SPF chickens and have good immune protection effects on NDV virulent strains, ILTV virulent strains and IBDV virulent strains. The invention provides an effective technical means for simultaneously preventing the Newcastle disease and the chicken infectious laryngotracheitis or simultaneously preventing the Newcastle disease, the chicken infectious bursal disease and the chicken infectious laryngotracheitis.

The invention belongs to the technical field of poultry vaccines, and particularly relates to a chicken new tributary method adeno-quintuplet vaccine and a preparation method thereof.The chicken new tributary method adeno-quintuplet vaccine comprises chicken Newcastle disease venom, infectious bronchitis venom, avian influenza venom, infectious bursal disease virus liquid and fowl adenovirus venom, and the preparation method of the Newcastle disease venom comprises the steps that firstly, frozen MDCK suspension cells are provided; the frozen MDCK suspension cells are recovered at the temperature of 40-45 DEG C; 2, transferring the resuscitated MDCK suspension cells to a serum-free culture medium; according to the invention, the inactivated vaccine is prepared from the Newcastle disease venom, the infectious bronchitis venom, the avian influenza venom, the infectious bursal disease virus liquid and the fowl adenovirus venom by adopting a superstrong concentration process and a high-quality adjuvant, so that after animals are immunized, antibodies are generated quickly, the titer is high, the protection period is long, and the occurrence and spreading of epidemic diseases are prevented; and people can conveniently put multi-combined vaccines to cope with continuously changing epidemic disease prevention and control situations.

The present disclosure relates to a chimeric virus expressing an infectious bursal disease antigen and a vaccine composition comprising same.

The invention provides a recombinant herpesvirus turkey for co-expressing a Newcastle disease virus F gene and an infectious bursal disease virus VP2 gene as well as a construction method and application of the recombinant herpesvirus turkey. The recombinant clone technology is utilized, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus super virulent strain VP2 gene is inserted between 95322-95323 nucleotides of a turkey herpesvirus FC126 strain, and the recombinant clone with the F gene and the VP2 gene expression framework inserted into a turkey herpesvirus genome is constructed and obtained. And the recombinant herpesvirus turkey vaccine strain H20101 for co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus VP2 gene is rescued and obtained by the recombinant herpesvirus turkey vaccine strain H20101. The vaccine prepared from the recombinant turkey herpesvirus provided by the invention can provide dual protection against super virulent Newcastle disease virus and infectious bursal disease virus, overcomes the defect that the existing vaccine is difficult to prevent two diseases by one injection, and has a good market application prospect.